Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Jazz Pharmaceuticals is expected to report a year-over-year earnings decline with higher revenues when it releases Q3 2026 results on November 2. With an Earnings ESP of 0% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has beaten consensus estimates in 3 of the last 4 quarters but missed the most recent quarter by 5.46%.